» Download Public Reports
About 1 100 reports
- Country report
- April 2013
- 10 pages
February 2013
... As a whole and to seek shareholder approval for the placings. Background to and reasons for the placings e-therapeutics is a drug discovery and development company with a proprietary platform technology ...
March 2013
... For patients in spain. Epidermolysis bullosa , scl Scleroderma, cf cystic fibrosis, hemo Prader-willi syndrome, xfr Fragile x syndrome. Direct non ...
March 2013
... In revenues last year, and earned $177.5 Million in net income. Its cro division generated 74% of its revenues. Also noted: quintiles helped develop or commercialize 85% of the central nervous system drugs ...
February 2013
... Of the global fight against infectious diseases Kofi annan, nobel peace prize laureate and former secretary- general of the united nations. Keppel street building and gardens. Anne koerber / lshtm 11keppel ...
April 2013
... Antiretroviral therapy; ci, confidence interval, efv, efavirenz; ftc, emtricitabine; str, single tablet regimen; tdf, tenofovir disoproxil fumarate. Total costs comprised inpatient days, outpatient and dayward ...
April 2013
... Nonsurgical polyp removal complete colonic examination age 35 years or older; no history of colorectal cancer, inflammatory bowel disease, or large bowel resection; satisfactory completion of a food ...
April 2013
... Official figures show. Circulatory conditions like heart disease remain the most common cause of death, contributing to a third of the deaths registered. But over the decade, mortality from ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 1 000 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
